Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTTION Systematic Review

作者：Williams Mark R; McKeown Andrew; Pressman Zachary; Hunsinge Matthew; Lee Kendrick; Coplan Paul; Gilron Ian; Katz Nathaniel P; McDermott Michael P; Raja Srinivasa N; Rappaport Bob A; Rowbotham Michael C; Turk Dennis C; Dworkin Robert H; Smith Shannon M^*

来源：Journal of Pain, 2016, 17(11): 1137-1149.

DOI：10.1016/j.jpain.2016.07.006

• Adverse event
• pain
• clinical trial
• intravenous
• invasive
• reporting

Thorough assessment and reporting of adverse events (AEs) facilitates a detailed understanding of a treatment's risk benefit profile. Although the Consolidated Standards of Reporting Trials (CONSORT) 2004 statement provides recommendations regarding AE reporting, adherence to these standards is often inadequate. We investigated AE reporting in clinical trials of intravenous and invasive pain treatments published in 6 major anesthesiology and pain journals between 2000 to 2003 and 2006 to 2012. We examined whether AE reporting improved after publication of the 2004 CONSORT recommendations and also comprehensively reviewed AE assessment using the Anal-gesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) AE reporting recommendations. No improvement was found overall in CONSORT harms reporting scores from pre- to postpublication of the CONSORT recommendations, with only 5 of 10 fulfilled on average. AE reporting assessed using the ACTTION coding manual was generally inadequate, and 8% of articles failed to report any AE information at all. Anesthesiology and pain journals were similar in AE reporting quality, although industry-sponsored trials reported more AE information than nonindustry sponsored trials. Improvement is needed in AE reporting in analgesic clinical trials. The CONSORT checklist and ACTTION AE recommendations can assist investigators and editors in improving clinical trial transparency and quality.
Perspective: This systematic review of AE reporting in intravenous and invasive pain treatment trials shows that little improvement has been made since the 2004 CONSORT harms reporting guidelines. Better assessment and reporting of treatment AEs is necessary to understand the full clinical effect of intravenous and invasive treatments.

• 出版日期2016-11